Literature DB >> 1476170

Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells.

K Janakidevi1, M A Fisher, P J Del Vecchio, C Tiruppathi, J Figge, A B Malik.   

Abstract

Endothelin-1 (ET-1), a 21-amino acid peptide released from the endothelium, elicits a variety of biological effects that include vascular smooth muscle cell (VSMC) contraction, release of secondary mediators, and cell proliferation. The present study was undertaken to examine the proliferative potential of ET-1 toward pulmonary artery VSMC in culture. In the presence of low serum and epidermal growth factor (EGF), ET-1 stimulated marked DNA synthesis and proliferation of VSMC. The contributing factor from serum appeared to be platelet-derived growth factor (PDGF) because the antibody to PDGF eliminated the stimulatory activity. The antibody to EGF also prevented the stimulation, suggesting that both PDGF and EGF are required for the full expression of the VSMC growth-promoting activity of ET-1. A paradoxical aspect of ET-1 effect on VSMC was the ability of ET-1 to inhibit the EGF-stimulated DNA synthesis when the two factors were added together to a high baseline DNA synthetic activity. The inhibition was prevented if ET-1 was added 12-18 h after the addition of EGF or if ET-1 and EGF were added to a protein kinase C-depleted VSMC. The inhibition by ET-1 may be mediated by protein kinase C activation followed by inhibition of EGF binding to its receptor. The results indicate that ET-1 under appropriate conditions can modulate the growth of pulmonary artery VSMC in both positive and negative directions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1476170     DOI: 10.1152/ajpcell.1992.263.6.C1295

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

Review 1.  Bosentan and the endothelin system in congestive heart failure.

Authors:  S H Ellahham; V Charlon; Z Abassi; K A Calis; W K Choucair
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

Review 2.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

3.  EndothelinB receptor-mediated contraction in human pulmonary resistance arteries.

Authors:  K M McCulloch; C C Docherty; I Morecroft; M R MacLean
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 4.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Paracrine effect of human vascular endothelial cells on human vascular smooth muscle cell proliferation: transmembrane co-culture method.

Authors:  H Yoshida; M Nakamura; S Makita; K Hiramori
Journal:  Heart Vessels       Date:  1996       Impact factor: 2.037

6.  Developmental changes in the functional, biochemical and molecular properties of rat bladder endothelin receptors.

Authors:  Parviz Afiatpour; Jamshid Latifpour; Wataru Takahashi; Makoto Yono; Harris E Foster; Kazuyoshi Ikeda; Mehdi Pouresmail; Robert M Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-17       Impact factor: 3.000

7.  Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone.

Authors:  Graeme A Deuchar; Andrew Docherty; Margaret R MacLean; Martin N Hicks
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

8.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 9.  Cell signaling by protein carbonylation and decarbonylation.

Authors:  Chi Ming Wong; Lucia Marcocci; Lingling Liu; Yuichiro J Suzuki
Journal:  Antioxid Redox Signal       Date:  2010-03       Impact factor: 8.401

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.